Balsm Alofoq - Public Comps and Valuation Multiples

Balsm Alofoq Overview

About Balsm Alofoq

Balsm Alofoq Medical Co operates in the medical sector. Its activities include medical services, specialized clinics and medical complexes, medical operations, and the import and supply of medical devices and supplies to all regions of the Kingdom of Saudi Arabia.

Founded

2012

HQ

Employees

n/a

Website

balsmalofoq-mc.com

Sectors

Medical Supplies

Financials

Last FY Revenue $5.3M

Last FY EBITDA $1.7M

EV

$14.7M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Balsm Alofoq Financials

See Balsm Alofoq valuation multiples based on analyst estimates

Balsm Alofoq P&L

In the most recent fiscal year, Balsm Alofoq reported revenue of $5.3M and EBITDA of $1.7M.

Balsm Alofoq expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Balsm Alofoq valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$5.3M	XXX	XXX	XXX
Gross Profit	XXX	$2.5M	XXX	XXX	XXX
Gross Margin	XXX	47%	XXX	XXX	XXX
EBITDA	XXX	$1.7M	XXX	XXX	XXX
EBITDA Margin	XXX	32%	XXX	XXX	XXX
EBIT	XXX	$1.4M	XXX	XXX	XXX
EBIT Margin	XXX	26%	XXX	XXX	XXX
Net Profit	XXX	$1.3M	XXX	XXX	XXX
Net Margin	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Balsm Alofoq including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Balsm Alofoq achieved $5.3M in revenue and $1.7M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$5.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$2.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	47.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$1.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	31.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$1.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	26.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$1.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	24.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Balsm Alofoq

This financial data table provides comprehensive performance metrics for Balsm Alofoq, a company based in Saudi Arabia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Balsm Alofoq reported $5.3M in total revenue.
Fiscal year EBITDA was $1.7M.
The company maintained a gross profit margin of 47.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 31.8%.
Net profit margin reached 24.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Balsm Alofoq. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Balsm Alofoq Stock Performance

Balsm Alofoq has current market cap of SAR 71.5M (or $19.1M), and EV of SAR 55.1M (or $14.7M).

Market Cap Evolution

Balsm Alofoq Stock Data

As of October 3, 2025, Balsm Alofoq's stock price is SAR 57 (or $15).

See Balsm Alofoq trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$14.7M	$19.1M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Balsm Alofoq Valuation Multiples

Balsm Alofoq's trades at 2.8x EV/Revenue multiple, and 8.7x EV/EBITDA.

See valuation multiples for Balsm Alofoq and 15K+ public comps

Balsm Alofoq Financial Valuation Multiples

As of October 3, 2025, Balsm Alofoq has market cap of $19.1M and EV of $14.7M.

Equity research analysts estimate Balsm Alofoq's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Balsm Alofoq's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$19.1M	XXX	$19.1M	XXX	XXX	XXX
EV (current)	$14.7M	XXX	$14.7M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	2.8x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	8.7x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	10.7x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	15.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	10.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Balsm Alofoq Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Balsm Alofoq Margins & Growth Rates

Balsm Alofoq's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Balsm Alofoq's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Balsm Alofoq's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Balsm Alofoq and other 15K+ public comps

Balsm Alofoq Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	32%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	21%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial